Sanofi (SNY) Presents Positive Diabetes Data On IGlarLixi (revised)

Sanofi (NYSE:SNY) announced positive results of a new post-hoc analysis of data from a phase III trial that evaluated its investigational candidate, iGlarLixi, a titratable fixed-ratio combination of insulin glargine and lixisenatide.

iGlarLixi was tested for mealtime blood sugar (post-prandial glucose (PPG)) control in adults with type 2 diabetes in the LixiLan-L Trial. The post-hoc analysis of the trial data showed that iGlarLixi led to greater PPG control compared to insulin glargine 100 Units/mL.

The analysis showed that a significantly higher proportion of participants attained the PPG target after 30 weeks. The percentage of patients achieving the PPG target at week 30 was 16.4% higher in the fixed-ratio combination group than the insulin glargine 100 Units/mL arm at 0.5 hour. At one hour and two hours, the proportions of patients achieving the PPG target in the fixed-ratio combination group were 22.4% and 28.2% higher, respectively, compared to the insulin glargine 100 Units/mL arm.

This data was presented at the European Association for the Study of Diabetes’ (EASD) 52nd Annual Meeting in Munich, Germany.

Presently, iGlarLixi is under review in the U.S. and Europe. Sanofi also presented new patient-level meta-analysis data from the EDITION phase III trials in type 2 diabetes at the EASD. Results showed that patients treated with its diabetes drug, Toujeo, demonstrated a consistently lower rate of hypoglycemia compared to its other diabetes drug Lantus(R) at all levels of hba1c (average blood glucose over the previous three months) control.

Zacks Rank & Key Picks

Sanofi currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in health care sector include ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) , Cambrex Corp. (NYSE:CBM) and Johnson & Johnson (NYSE:JNJ) . While both ANI Pharma and Cambrex sport a Zacks Rank #1 (Strong Buy), Johnson & Johnson carries a Zacks Rank #2 (Buy).

(We are reissuing this article to correct a mistake. The original article, issued yesterday, September 14, 2016, should no longer be relied upon.)